个人情况介绍、概览

张莹石，女，博士，副教授。2012年毕业于沈阳药科大学，获理学学士学位，2015年于沈阳药科大学获药学（临床药学方向）硕士学位，2018年获沈阳药科大学临床药学专业博士学位。2018年起任职于临床药学教研室，2021.1-2024.4于北部战区总医院博士后工作站进行博士后研究。2025年12月被聘为沈阳药科大学副教授。作为课题负责人主持辽宁省科技厅项目2项，辽宁省教育厅项目2项，发表高水平SCI论文10余篇。

人才称号、社会兼职等（限填10项）

1.辽宁省药学会第十届理事会临床药学与科学传播专业委员会委员。

主要研究方向（限填3项）

研究方向一：小分子化合物抗肿瘤活性与机制研究

研究方向二：肿瘤个体化精准治疗策略循证研究

研究方向三：抗肿瘤药物心脏损伤作用及机制研究

主持、参与的科研项目（含科研获奖等情况）（限填10项）

1.辽宁省科学技术厅, 省博士科研启动基金计划项目, 2020-BS-125, ZLDI-8通过介导Notch1-Integrinβ1信号通路抑制肝细胞癌复发的机制研究, 2020-05 至 2022-10, 3万元, 结题, 主持。

2.辽宁省教育厅, 青年项目, LJKQZ20222349, ZLDI-8调节Integrinβ1-MMP9信号通路抑制肝细胞癌转移及复发的作用与机制研究, 2022-9 至 2024-11, 3万元, 结题, 主持。

3.辽宁省教育厅，LJ212510163014, 质子泵抑制剂调控GPR81/PUFA/ACSL1通路介导 铁死亡影响CDK4/6抑制剂疗效的机制研究, 2025-7至2027年6月，在研，主持

4.辽宁省科学技术厅, 2025-MSLH-653，新型ADAM8/17双靶点抑制剂的发现及其抗肝内胆管癌作用机制研究，2025-11至2027.10，在研，主持

近年来发表代表性论文(限第一作者或通讯作者，SCI须写明影响因子)：（限填10篇）

[1] Yingshi Zhang, Dandan Li, Qiyu Jiang, Shuang Cao, Huiwei Sun, Yantao Chai, Xiaojuan Li, Tianshu Ren, Ruichuang Yang, Fan Feng*, Bo-an Li*, Qingchun Zhao*. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells.Cell Death & Disease. 2018; 9: 743-756 (IF=5.959).

[2] Hongyuan Lu, Haixiao Chu, Yuxin Tan, Xiaochun Qin, Mingyue Liu, Jingda Li, Tianshu Ren, Yingshi Zhang*(共同通讯作者), Qingchun Zhao*. Novel ADAM-17 inhibitor ZLDI-8 inhibits the metastasis of Hepatocellular carcinoma by reversing epithelial mesenchymal transition in vitro and in vivo. Life Science. 2020; 244:117343-117355 (IF=5.037).

[3] Hongyuan Lu, Yuxin Zu, Xiaowen Jiang, Xiaotong Sun, Tianyi Liu, Ruolan Li, Qiong Wu, Yingshi Zhang*(共同通讯作者), Qingchun Zhao*. Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo. Pharmacological research, 2019;148:104406-104418 (IF=5.893).

[4] Tianshu Ren, Hui Jia, Qiong Wu, Yan Zhang, Qun Ma, Dong Yao, Xudong Gao, Danni Xie, Zihua Xu, Qingchun Zhao*, Yingshi Zhang*(共同通讯作者). Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab. Frontiers in oncology. 2022;12:829059 (IF=5.738).

[5] Xiaowen Jiang, Zihua Xu, Dong Yao, Xin Liu, Wenwu Liu, Nan Wang, Xiang Li, Yao Diao, Yingshi Zhang*(共同通讯作者), Qingchun Zhao*. An integrated multi-omics approach revealed the regulation of melatonin on age-dependent mitochondrial function impair and lipid dyshomeostasis in mice hippocampus. Pharmacological research. 2022;179:106210 (IF=9.3).

[6] Yingshi Zhang, Chang Xu, Xiangbo Xu, Lingxiang Ma, Ruolan Li, Zihua Xu*, Qingchun Zhao*. Pharmacokinetics, tissue distribution, and antitumor activity of a novel compound, NY-2, in non-small cell lung cancer. Frontiers in Pharmacology. 2023; 13:1074576 (IF=5.988).

[7] Chang Xu, Xudong Gao, Tianshu Ren, Hefeng Geng, Kaisi Yang, Yaoguang Huang, Weige Zhang, Shanbo Hou, Aigang Song, Yingshi Zhang*(共同通讯作者), Qingchun Zhao*. The ADAM17 inhibitor ZLDI-8 sensitized hepatocellular carcinoma cells to sorafenib through Notch1-integrin β-talk. Pharmacol Res. 2024;203:107142. (IF=10.5)

[8] Hefeng Geng, Fangyuan Zheng, Wentao Sun, Shuoqi Huang, Zhiya Wang, Kaisi Yang, Chengkang Wang, Caizhi Tian, Chang Xu, Guanchao Zhai, Mingyi Zhao, Shanbo Hou, Aigang Song, Yingshi Zhang*(共同通讯作者), Qingchun Zhao*. Effect and mechanism of novel HDAC inhibitor ZDLT-1 in colorectal cancer by regulating apoptosis and inflammation. Int Immunopharmacol. 2024; 143(1):113333. (IF=4.7)

[9] Yingshi Zhang, Xiangbo Xu, Kaisi Yang, Shuai Wang, Tianqi Zhang, Fuhai Hui, Fangyuan Zheng, Hefeng Geng, Chang Xu, Fanghua Xun, Ziang Xu, Chengkang Wang, Shanbo Hou, Aigang Song, Tianshu Ren*, Qingchun Zhao*. The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis. European Journal of Pharmacology. 2024;983:176952. (IF=4.2).

[10] Yingshi Zhang^#, Jiayue Gao^#, Yu Bao, Yang Liu, Yimeng Tong, Shuqing Jin, Qingchun Zhao*.Diagnostic accuracy and prognostic significance of osteopontin in liver cirrhosis and hepatocellular carcinoma: a Meta-analysis. Biomarkers. 2021;27:13-21 (IF=2.663).

主编或参编的教材、专著（限填10项）

无

专利及其他（限填10项）

无